Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia
© 2024. The Author(s)..
RATIONALE: Acute respiratory distress syndrome (ARDS) is a life-threatening critical care syndrome commonly associated with infections such as COVID-19, influenza, and bacterial pneumonia. Ongoing research aims to improve our understanding of ARDS, including its molecular mechanisms, individualized treatment options, and potential interventions to reduce inflammation and promote lung repair.
OBJECTIVE: To map and compare metabolic phenotypes of different infectious causes of ARDS to better understand the metabolic pathways involved in the underlying pathogenesis.
METHODS: We analyzed metabolic phenotypes of 3 ARDS cohorts caused by COVID-19, H1N1 influenza, and bacterial pneumonia compared to non-ARDS COVID-19-infected patients and ICU-ventilated controls. Targeted metabolomics was performed on plasma samples from a total of 150 patients using quantitative LC-MS/MS and DI-MS/MS analytical platforms.
RESULTS: Distinct metabolic phenotypes were detected between different infectious causes of ARDS. There were metabolomics differences between ARDSs associated with COVID-19 and H1N1, which include metabolic pathways involving taurine and hypotaurine, pyruvate, TCA cycle metabolites, lysine, and glycerophospholipids. ARDSs associated with bacterial pneumonia and COVID-19 differed in the metabolism of D-glutamine and D-glutamate, arginine, proline, histidine, and pyruvate. The metabolic profile of COVID-19 ARDS (C19/A) patients admitted to the ICU differed from COVID-19 pneumonia (C19/P) patients who were not admitted to the ICU in metabolisms of phenylalanine, tryptophan, lysine, and tyrosine. Metabolomics analysis revealed significant differences between C19/A, H1N1/A, and PNA/A vs ICU-ventilated controls, reflecting potentially different disease mechanisms.
CONCLUSION: Different metabolic phenotypes characterize ARDS associated with different viral and bacterial infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Critical care (London, England) - 28(2024), 1 vom: 27. Feb., Seite 63 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Chel Hee [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| Anmerkungen: |
Date Completed 29.02.2024 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13054-024-04843-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369040066 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369040066 | ||
| 003 | DE-627 | ||
| 005 | 20240405233646.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-024-04843-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM369040066 | ||
| 035 | |a (NLM)38414082 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Chel Hee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.02.2024 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a RATIONALE: Acute respiratory distress syndrome (ARDS) is a life-threatening critical care syndrome commonly associated with infections such as COVID-19, influenza, and bacterial pneumonia. Ongoing research aims to improve our understanding of ARDS, including its molecular mechanisms, individualized treatment options, and potential interventions to reduce inflammation and promote lung repair | ||
| 520 | |a OBJECTIVE: To map and compare metabolic phenotypes of different infectious causes of ARDS to better understand the metabolic pathways involved in the underlying pathogenesis | ||
| 520 | |a METHODS: We analyzed metabolic phenotypes of 3 ARDS cohorts caused by COVID-19, H1N1 influenza, and bacterial pneumonia compared to non-ARDS COVID-19-infected patients and ICU-ventilated controls. Targeted metabolomics was performed on plasma samples from a total of 150 patients using quantitative LC-MS/MS and DI-MS/MS analytical platforms | ||
| 520 | |a RESULTS: Distinct metabolic phenotypes were detected between different infectious causes of ARDS. There were metabolomics differences between ARDSs associated with COVID-19 and H1N1, which include metabolic pathways involving taurine and hypotaurine, pyruvate, TCA cycle metabolites, lysine, and glycerophospholipids. ARDSs associated with bacterial pneumonia and COVID-19 differed in the metabolism of D-glutamine and D-glutamate, arginine, proline, histidine, and pyruvate. The metabolic profile of COVID-19 ARDS (C19/A) patients admitted to the ICU differed from COVID-19 pneumonia (C19/P) patients who were not admitted to the ICU in metabolisms of phenylalanine, tryptophan, lysine, and tyrosine. Metabolomics analysis revealed significant differences between C19/A, H1N1/A, and PNA/A vs ICU-ventilated controls, reflecting potentially different disease mechanisms | ||
| 520 | |a CONCLUSION: Different metabolic phenotypes characterize ARDS associated with different viral and bacterial infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a H1N1 | |
| 650 | 4 | |a Metabolomics | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Lysine |2 NLM | |
| 650 | 7 | |a K3Z4F929H6 |2 NLM | |
| 650 | 7 | |a Pyruvates |2 NLM | |
| 700 | 1 | |a Banoei, Mohammad M |e verfasserin |4 aut | |
| 700 | 1 | |a Ansari, Mariam |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Lamontagne, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Griesdale, Donald |e verfasserin |4 aut | |
| 700 | 1 | |a Lasry, David E |e verfasserin |4 aut | |
| 700 | 1 | |a Demir, Koray |e verfasserin |4 aut | |
| 700 | 1 | |a Dhingra, Vinay |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Karen C |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Terry |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Sweet, David |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John |e verfasserin |4 aut | |
| 700 | 1 | |a Slutsky, Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Murthy, Srinivas |e verfasserin |4 aut | |
| 700 | 1 | |a Singer, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Patrick, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Todd C |e verfasserin |4 aut | |
| 700 | 1 | |a Boyd, John H |e verfasserin |4 aut | |
| 700 | 1 | |a Walley, Keith R |e verfasserin |4 aut | |
| 700 | 1 | |a Fowler, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Haljan, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Vinh, Donald C |e verfasserin |4 aut | |
| 700 | 1 | |a Mcgeer, Alison |e verfasserin |4 aut | |
| 700 | 1 | |a Maslove, David |e verfasserin |4 aut | |
| 700 | 1 | |a Mann, Puneet |e verfasserin |4 aut | |
| 700 | 1 | |a Donohoe, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, Geraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Rocheleau, Genevieve |e verfasserin |4 aut | |
| 700 | 1 | |a Trahtemberg, Uriel |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Anand |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Ma |e verfasserin |4 aut | |
| 700 | 1 | |a Dos Santos, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Winston, Brent W |e verfasserin |4 aut | |
| 700 | 0 | |a *ARBs CORONA I. Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Russell, J A |e investigator |4 oth | |
| 700 | 1 | |a Walley, K R |e investigator |4 oth | |
| 700 | 1 | |a Boyd, J |e investigator |4 oth | |
| 700 | 1 | |a Lee, T |e investigator |4 oth | |
| 700 | 1 | |a Singer, J |e investigator |4 oth | |
| 700 | 1 | |a Sweet, D |e investigator |4 oth | |
| 700 | 1 | |a Tran, K |e investigator |4 oth | |
| 700 | 1 | |a Reynolds, S |e investigator |4 oth | |
| 700 | 1 | |a Haljan, G |e investigator |4 oth | |
| 700 | 1 | |a Cheng, M |e investigator |4 oth | |
| 700 | 1 | |a Vinh, D |e investigator |4 oth | |
| 700 | 1 | |a Lee, T |e investigator |4 oth | |
| 700 | 1 | |a Lamontagne, F |e investigator |4 oth | |
| 700 | 1 | |a Winston, B |e investigator |4 oth | |
| 700 | 1 | |a Rewa, O |e investigator |4 oth | |
| 700 | 1 | |a Marshall, J |e investigator |4 oth | |
| 700 | 1 | |a Slutsky, A |e investigator |4 oth | |
| 700 | 1 | |a McGeer, A |e investigator |4 oth | |
| 700 | 1 | |a Sivanantham, V |e investigator |4 oth | |
| 700 | 1 | |a Fowler, R |e investigator |4 oth | |
| 700 | 1 | |a Maslove, D |e investigator |4 oth | |
| 700 | 1 | |a Patrigeon, S Perez |e investigator |4 oth | |
| 700 | 1 | |a Burns, K D |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care (London, England) |d 1997 |g 28(2024), 1 vom: 27. Feb., Seite 63 |w (DE-627)NLM097399787 |x 1466-609X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:1 |g day:27 |g month:02 |g pages:63 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13054-024-04843-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 1 |b 27 |c 02 |h 63 | ||